ArticlesTherapeutic Drug Monitoring in Turkey: Experiences From IstanbulYamantürk, Pinar; Özek, Mehmet; Sevgi, Serhan; Eroğlu, LütfiyeAuthor Information From the Department of Pharmacology and Clinical Pharmacology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey Received January 4, 2000; accepted March 24, 2000. Address correspondence and reprint requests to Pinar Yamantürk, Istanbul University, Istanbul Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology, 34390, Ĉapa, Istanbul, Turkey Data were presented in part in the session, “Management of Adverse Drug Reactions, Including Interactions, in Clinical Practice” at the Seventh Annual Meeting of the European Society of Pharmacovigilance held in Ankara, Turkey, September 23–24, 1999. Therapeutic Drug Monitoring: October 2000 - Volume 22 - Issue 5 - p 545-548 Buy Abstract Therapeutic drug monitoring (TDM) has assumed an important place in patient management in the last few decades. In this study, serum drug levels determined in 7759 specimens sent to the Department of Pharmacology and Clinical Pharmacology in 1994 and 1998 for TDM were retrospectively evaluated. Monitored drugs were carbamazepine, valproate, phenytoin, phenobarbital, digoxin, theophylline, and salicylate. The comparison of the results obtained for the relevant 2 years showed that there was a remarkable increase in the number of requests for TDM per year and in the rate of serum drug levels that were within therapeutic range. Serum antiepileptic drug level monitoring accounted for a major part of the data. Overall data suggest that the use of TDM in antiepileptic drugs is improving; conversely, digoxin and theophylline are still not being properly monitored. In this study, the results are discussed in the light of rational TDM criteria. © 2000 Lippincott Williams & Wilkins, Inc.